FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine, namely to oncology, and can be used for treating non-small cells lung cancer (NSCLC) with resistance to tyrosine kinase inhibitors of epidermal growth factor receptors. According to the invention, methods include administering a thiochromeno[2,3-c]quinoline-12-one – derivative N19.
EFFECT: use of the inventions allows treating resistant NSCLC by suppressing HSP90, epidermal growth factor receptors, and cMET without retinal cytotoxicity.
13 cl, 4 ex, 14 dwg
| Title |
Year |
Author |
Number |
| APPLICATION OF IMIDAZOQUINOLINES FOR TREATMENT OF EGFR-DEPENDENT DISEASES OR DISEASES WITH AQUIRED RESISTANCE TO AGENTS BINDING MEMBERS OF EGFR FAMILY |
2008 |
- Garsija-Ehcheverrija Karlos
- Maira Sove-Mishel'
|
RU2481838C2 |
| COMBINATION OF EGFR INHIBITOR AND MEK INHIBITOR FOR USE IN TREATMENT OF NRAS MUTATED CANCER |
2015 |
- Cross Darren Anthony Edward
- Eberlein Catherine Anne
|
RU2683276C2 |
| THERAPEUTIC COMPOSITION FOR REDUCING RESISTANCE TO TYROSINE KINASE INHIBITORS |
2016 |
- D'Hondt, Erik
- Molina Vila, Miguel, Angel
|
RU2735493C2 |
| USING PYRIMIDINE DERIVATIVES FOR TREATING EGFR-DEPENDENT DISEASES OR DISEASES WITH ACQUIRED RESISTANCE TO AGENTS AGAINST EGFR FAMILY |
2009 |
- Garsia-Ehcheverria Karlos
- Maira Sove-Mishel'
|
RU2496500C2 |
| NEW COMBINATION OF 3-[(3-{[4-(4-MORPHOLINYLMETHYL)-1N-PYRROL-2-YL]METHYLENE}-2-OXO-2,3-DIHYDRO-1N-INDOL-5-YL)METHYL]-1,3-THIAZOLIDINE-2,4-DIONE AND TYROSINE KINASE INHIBITOR EGFR |
2016 |
- Berbridzh Majkl
- Kattan Valeri
- Zhak-Beskon Anne
|
RU2695362C2 |
| IPP COMPLEX AS MARKER FOR ERLOTINIB TREATMENT |
2011 |
- Augustin, Anzhelik
- Dyushato-Ngujen, Gijmett
- Essyu, Loran
- Gollen, Sabrina
- Klugkhammer, Barbara
- Lamerts, Ens
- Langen, Khanno
- Majstermann, Elen
- Shajblikh, Stefan
- Tsouros, Manuel
|
RU2600828C2 |
| DETERMINATION OF CELL SENSITIVITY TO TREATMENT WITH B-Raf INHIBITOR BY DETECTION OF K-ras MUTATION AND LEVELS OF RTK EXPRESSION |
2010 |
- Khatzivassiliu Dzhordzhija
- Malek Shiva
|
RU2553379C2 |
| COMBINATION THERAPY USING DIARYL MACROCYCLIC COMPOUNDS |
2018 |
- Cui, Jingrong, Jean
- Zhai, Dayong
|
RU2784853C2 |
| USE OF 2-CARBOXAMIDE-CYCLOAMINO UREA DERIVATIVES IN TREATMENT OF EGFR-DEPENDENT DISEASES OR DISEASES WITH ACQUIRED RESISTANCE TO AGENTS TARGETED AT EGFR-FAMILY MEMBERS |
2011 |
- Brakhmann, Zaskia Mariya
- Fritch, Kristin
- Mera, Saver-Mishel
- Shnell, Kristian Rene
- Garsiya-Echeverriya, Karlos
|
RU2589695C2 |
| COMBINED PRODUCTS CONTAINING TYROSINE KINASE INHIBITORS AND THEIR USE |
2013 |
- Tidt Ralf
- Shatene-Rivode Kristian
- Ito Moriko
- Pen Bin
- Gun In
- Akimov Mikhail
|
RU2660354C2 |
